CClinicalTrials.gg
CompletedNCT03113578Updated Dec 2, 2017

Evaluation of the DiLumen Device During Colonoscopy

An observational study in Colon Polyp, sponsored by Lumendi, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-02.

Sponsored by Lumendi, LLC · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

This is an observational registry study collecting data on the clinical performance of the study device (DiLumen™ ) for its intended use. The primary objective is to evaluate functional outcomes of the DiLumen device in humans. The secondary objective is to evaluate safety characteristics of the DiLumen device.

Read the detailed description

The DiLumen™ Endolumenal Interventional Platform is a non-sterile, single-use, close-fitting sleeve that fits securely over a standard endoscope to stabilize it in the large intestine, and facilitates use of the endoscope for optical visualization, diagnosis, and treatment. It was developed by MINT (Minimally Invasive New Technology) at Weill Cornell. The technology has been licensed to Lumendi for commercialization.

The DiLumen Endolumenal Interventional Platform ("DiLumen" or "the device") is an accessory to an endoscope. The DiLumen dual balloon accessory is intended for use with any standard endoscope that has a distal tip outer diameter of 12.5 - 14.3 mm and a working length of 1680 mm or greater. The device is indicated to ensure complete positioning of an endoscope in the large intestine and assist with optical visualization, diagnosis, and endoscopic treatment.

The device received 510k clearance on Dec 6, 2016. The device is fully disposable, and consists of six major components that form its primary mechanical structure: (1) Fore Balloon; (2) Aft Balloon; (3) Sleeve; (4) Base; (5) Push Rod Mechanism; and (6) Inflation System.

The DiLumen utilizes two balloons to position and stabilize the endoscope within a patient's large intestine. After the device is installed over the endoscope, the endoscope/DiLumen are navigated to the target zone with the balloons deflated. The first balloon, the Aft balloon, is attached to the DiLumen sleeve. Once the clinician is at the target site, the Aft Balloon will be inflated until it contacts the intestinal wall near the proximal end of the articulating section of an endoscope. The second balloon, the Fore Balloon, is also attached to the sleeve via two flexible extension Push Rods and is deployed at the distal end of the endoscope at a variable distance. Once extended and inflated, the Fore Balloon contacts the patient's intestinal wall, and in combination with the Aft Balloon, creates an isolated diagnostic or therapeutic zone within a patient's large intestine. Both balloons are inflated or deflated with ambient air independently using an Inflation Handle with a squeeze bulb. The balloons assist with accessing and visualization of lesions behind folds and turns in the intestine, stabilizing the endoscope distal tip and establishing a Therapeutic Zone (TZ). Required insufflation within the therapeutic zone is minimized compared to typical colorectal endoscopic procedures, because the balloons enclose only a small portion (approximately 23 cm) of the large intestine.

The balloons and sleeve are designed to permit the usage of any standard endoscopic tool (such as biopsy forceps, snare, needle, etc.) through the endoscope working channel. The endoscope flexibility, maneuverability and functionalities (such as visualization, suction, insufflations, etc.) are unaffected by the presence of the DiLumen.

02

Conditions studied

  • Colon Polyp

Browse trials for

Keywords

  • Balloon enteroscopy
  • colonoscopy
  • polyps
03

In context

Colonic Polyps

318 studies on the registry are indexed under Colonic Polyps; 54 are open to participants now.

This study's enrollment of 30 is below the median of 475 across 92 observational studies indexed under Colonic Polyps.

Browse Colonic Polyps studies →

Lead sponsor

Lumendi, LLC is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients listed for routine surveillance colonoscopy for colorectal cancer.

Inclusion criteria

  • Patients listed for routine surveillance colonoscopy for colorectal cancer and capable of giving informed consent

Exclusion criteria

Exclusion Criteria:

  • No patients less than 18 years of age.
  • Any contraindication to routine surveillance colonoscopy
  • History of open or laparoscopic colorectal surgery
  • History of Inflammatory Bowel Disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Interventions

  • DeviceDiLumen

    The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons

    Also known as: Endolumenal Interventional Platform

06

What researchers measure

Primary outcomes

  1. Performance

    Ability to reach cecum with the study device and scope \[Y or N\]

    Time frame: Duration of procedure

Secondary outcomes

  1. Incidence of Treatment Related Adverse Events

    No unintended visible mucosal injury on Dilumen withdrawal (above what is normally expected from colonoscopy)

    Time frame: Up to 3 months

  2. Performance

    Ability to inflate balloons in right colon and sigmoid colon and create a therapeutic zone \[Y or N\]

    Time frame: Duration of Procedure

07

Study locations

1 site
  • New York Presbyterian Hospital
    New York, New York 10065, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03113578
Lead sponsor
Lumendi, LLC
Collaborators
Weill Medical College of Cornell University
Responsible party
Reem Sharaiha (Assistant Professor of Medicine, Primary Investigator, Weill Medical College of Cornell University) — Principal investigator
First posted
Apr 13, 2017
Start date
Apr 26, 2017
Primary completion
Sep 27, 2017
Completion
Sep 27, 2017
Last update
Dec 2, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion